Actionable news
All posts from Actionable news
Actionable news in AGN: ALLERGAN Inc,

Teva Growth Stock


Teva Pharmaceuticals is rapidly expanding on multiple fronts.

Huge inroads are in progress to the 115+ billion dollar sales per year Japanese pharmaceutical markets.

Latest update on huge 40.5 billion dollar acquisition of Allergan's Actavis Generics.

Takeda and Teva Pharmaceutical Industries (NYSE:TEVA) are teaming up in an unusual triangular absorption-type company split. Teva Pharma Japan Inc and two Japanese pharmaceutical companies - one, a business unit of Takeda dealing in long listed products including generics, and the second is Taisho Pharma, a marketer of OTC products. In the end, this triangular split results in three operating businesses becoming two.

Teva will have controlling stakes in each succeeding business, "Teva Takeda Yakuhin" and "Teva Takeda Pharma".

Exciting Opportunity to Grow Sales in Japan

This news reveals the Jerusalem-based Teva, and their Teva Japan subsidiary, have successfully developed their entrance into the Japanese pharmaceutical business environment. The company obviously has its eye on the high-value Japanese consumer market.

Deloitte's research arm points out that Japan's pharmaceutical market did 115 billion dollars of business during 2013.

The Japanese Joint Venturers Long Track Record

Takeda and Taisho have extensive histories as participants in the Japanese economy. For example, back in 1927 Taisho's popular cough suppressant "Pabron" was launched.

Venerable Takeda Pharmaceuticals was founded in June of 1781. The years of success each Japanese company has enjoyed indicates to me that these businesses have well established distributor relationships. Teva now has the opportunity to flow their products through these two domestic company's elite distribution networks.

Takeda and Taisho have established relationships with Japanese doctors and...